SCHEMBL184960

SCHEMBL184960

O=C(O)C(O)C(O)C(=O)OC(C(=O)O)C(O)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.50
SRC P12931 1/20 0.37
TP53 P04637 1/20 0.31
PGD P52209 1/20 0.30
MMP1 P03956 1/20 0.30
MMP2 P08253 1/20 0.30
MMP3 P08254 1/20 0.30
MMP9 P14780 1/20 0.30
MMP13 P45452 1/20 0.30
HTT P42858 1/20 0.30
SLC1A3 P43003 1/20 0.30
SLC1A2 P43004 1/20 0.30
SLC1A1 P43005 1/20 0.30
CYP2C9 P11712 1/20 0.30
PDE4A P27815 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2200092 1.00 TSHR (0.50) TSHRSRCTP53PGDMMP1
SCHEMBL8145944 1.00 TSHR (0.50) TSHRSRCTP53PGDMMP1
SCHEMBL5691242 1.00 TSHR (0.50) TSHRSRCTP53PGDMMP1
SCHEMBL5691239 1.00 TSHR (0.50) TSHRSRCTP53PGDMMP1
SCHEMBL29292859 0.98 TSHR (0.48) TSHRSRCTP53
SCHEMBL20565536 0.98 TSHR (0.48) TSHRSRCTP53
SCHEMBL11054851 0.98 TSHR (0.48) TSHRSRCTP53
SCHEMBL17338717 0.98 TSHR (0.48) TSHRSRCTP53
Hydrochloric Acid SCHEMBL4441219 0.98 TSHR (0.48) TSHRSRCTP53
SCHEMBL1431069 0.97 TSHR (0.45) TSHRSRCTP53PGDMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4132506-B1 CARBOXYLATE LIGAND MODIFIED FERRIC IRON HYDROXIDE COMPOSITIONS FOR USE IN THE TREATMENT OR PREVENTION OF IRON DEFICIENCY ASSOCIATED WITH LIVER DISEASES NEMYSIS LTD (IE) 2024-05-15 EP claimed
US-11684572-B2 Methods for producing carboxylate ligand modified ferric iron hydroxide colloids and related compositions and uses UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2023-06-27 US claimed
US-20230134391-A1 Carboxylate Ligand Modified Ferric Iron Hydroxide Compositions for use in the Treatment or Prevention of Iron Deficiency Associated with Liver Diseases NEMYSIS Ltd. (IE) 2023-05-04 US claimed
EP-4132506-A1 CARBOXYLATE LIGAND MODIFIED FERRIC IRON HYDROXIDE COMPOSITIONS FOR USE IN THE TREATMENT OR PREVENTION OF IRON DEFICIENCY ASSOCIATED WITH LIVER DISEASES Nemysis Limited (IE) 2023-02-15 EP claimed
CN-108430964-B Methods for producing carboxylate ligand-modified ferric hydroxide colloids, and related compositions and uses 英国研究与创新署 2021-05-11 CN claimed
EP-3359519-B1 METHODS FOR PRODUCING CARBOXYLATE LIGAND MODIFIED FERRIC IRON HYDROXIDE COLLOIDS AND RELATED COMPOSITIONS AND USES RES & INNOVATION UK (GB) 2020-08-12 EP claimed
US-20200155453-A1 Methods for Producing Carboxylate Ligand Modified Ferric Iron Hydroxide Colloids and Related Compositions and Uses MEDICAL RESEARCH COUNCIL (GB) 2020-05-21 US claimed
US-10159661-B2 Penicillin retard composition for intramuscular injection SANDOZ AG (CH) 2018-12-25 US claimed
US-20180271784-A1 Methods for Producing Carboxylate Ligand Modified Ferric Iron Hydroxide Colloids and Related Compositions and Uses MEDICAL RESEARCH COUNCIL (GB) 2018-09-27 US claimed
US-20180036291-A1 Penicillin Retard Composition For Intramuscular Injection SANDOZ AG (CH) 2018-02-08 US claimed
EP-2376678-B1 SOLUTION AND PROCESS FOR INCREASING THE SOLDERABILITY AND CORROSION RESISTANCE OF A METAL OR METAL ALLOY SURFACE ATOTECH DEUTSCHLAND GMBH (DE) 2012-09-12 EP claimed
EP-2401227-A2 REACTION TUBE AND HYDROTHERMAL PROCESSING FOR THE WET CHEMICAL CO-PRECIPITATION OF OXIDE POWDERS Eestor, Inc. (US) 2012-01-04 EP claimed
US-7976791-B2 Portable chemical sterilizer THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 2011-07-12 US claimed
US-20110076152-A1 VENTILATOR WHEEL OR FAN WHEEL WITH ANTIBACTERIAL COATING EBM-PAPST MULFINGEN GMBH & CO. KG (DE) 2011-03-31 US claimed
US-20110053758-A1 REACTION TUBE AND HYDROTHERMAL PROCESSING FOR THE WET CHEMICAL CO-PRECIPITATION OF OXIDE POWDERS EESTOR, INC. (US) 2011-03-03 US claimed
EP-1228089-A2 SALT FORM OF A CONJUGATE USEFUL IN THE TREATMENT OF PROSTATE CANCER Merck & Co., Inc. (US) 2002-08-07 EP claimed
US-6355611-B1 SODIUM SALT OF PROSTATE SPECIFIC ANTIGEN CONJUGATE COMPOUND; USEFUL IN TREATMENT OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA MERCK & CO., INC. 2002-03-12 US claimed
WO-2001030804-A2 SALT FORM OF A CONJUGATE USEFUL IN THE TREATMENT OF PROSTATE CANCER MERCK & CO., INC. (US) 2001-05-03 WO claimed
EP-0435012-B1 2-part hair dyeing agent SUNSTAR KK (JP) 1994-04-27 EP claimed
CN-1052043-A 2-PART HAIR DYEING AGENTS SUNSTAR KK (JP) 1991-06-12 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10159661-B2 Penicillin retard composition for intramuscular injection GMPS, MMP1, ITPA TSHR 3871/4885SRC 3302/4885TP53 3821/4885
US-20180036291-A1 Penicillin Retard Composition For Intramuscular Injection GMPS, MMP1, ITPA TSHR 3871/4885SRC 3302/4885TP53 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.